We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Enzyme Found to Trigger the Immune System, Providing Clues on Alzheimer’s-Related Protein

By LabMedica International staff writers
Posted on 13 Jan 2015
Print article
New findings with a specific enzyme could provide more clues on presenilin functions, in addition to providing a better determination into how the immune system is controlled.

Already known to cut proteins, the enzyme SPPL3 (signal peptide peptidase-like 3) appears to have additional talents, according to new data. In its newly discovered role, SPPL3 has been found to function without chopping proteins to activate T cells, the immune system’s combat forces. Because its structure is similar to that of presenilin enzymes, which have been implicated in Alzheimer’s Disease (AD), the researchers hope their new findings will provide better treatment options for the debilitating disorder.

A summary of their findings was published on December 22, 2014, in the journal Molecular and Cellular Biology. “No one could have predicted that SSPL3 was involved in T cell activation,” stated Joel Pomerantz, PhD, an associate professor of biological chemistry at Johns Hopkins University (JHU; Baltimore, MD, USA). “It walks like a duck and quacks like a duck, but its duck-like abilities don’t come into play here.”

T cells are immune system cells that destroy invading cells and help activate other immune cells. When a foreign protein binds to a receptor protein on the outside of a T cell, a signal relay system is activated. It finishes when a protein called NFAT (nuclear factor of activated T cells) moves to the nucleus and triggers a number of genes to effectively prepare the T cell for battle. Some of what happens in between is known, however, Dr. Pomerantz and his colleagues wanted to find more players in the process.

The researchers searched for proteins that could increase NFAT’s activity and found SPPL3, an enzyme that proved essential to NFAT’s activation but had never before been implicated in immune system function. Additional testing accurately placed SPPL3 within the sequence of events that lead to NFAT activation.

SPPL3 lives in the membrane of the endoplasmic reticulum (ER), a ruffled, membrane-bound compartment inside the cell that helps process new proteins, where it seems to encourage interactions between STIM1 and Orai1, two known components of the NFAT signal relay system. However, SPPL3 was found to accomplish this without using its enzymatic, or protein-cutting, abilities. It also encourages the release of calcium from the ER, which contributes to the signaling system though it is unclear whether this is something it does directly or indirectly. “SPPL3 is a relatively uncharacterized protein that had never before been implicated in immune system function,” said Dr. Pomerantz. “It opens up a whole new set of scientific questions.”

Dr. Pomerantz believes that SPPL3 could be used as a drug target to either augment the activation of T cells in immunodeficient individuals or to suppress it in those with overactive immune systems. He also plans to study the ability of SPPL3 to mediate the influx of calcium into the cell and the release of calcium from the ER, since calcium is key to the functioning of many cell signaling networks.

Related Links:

Johns Hopkins University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.